In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy.

To understand the effects of substitution patterns on photosensitizing the ability of boron dipyrromethene (BODIPY), two structural variations that either investigate the effectiveness of various iodinated derivatives to maximize the "heavy atom effect" or focus on the effect of extended conjugation at the 4-pyrrolic position to red-shift their activation wavelengths were investigated. Compounds with conjugation at the 4-pyrrolic position were less photocytotoxic than the parent unconjugated compound, while those with an iodinated BODIPY core presented better photocytotoxicity than compounds with iodoaryl groups at the meso-positions. The potency of the derivatives generally correlated well with their singlet oxygen generation level. Further studies of compound 5 on HSC-2 cells showed almost exclusive localization to mitochondria, induction of G(2)/M-phase cell cycle block, and onset of apoptosis. Compound 5 also extensively occluded the vasculature of the chick chorioallantoic membrane. Iodinated BODIPY structures such as compound 5 may have potential as new photodynamic therapy agents for cancer.

[1]  H. Bergh,et al.  Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II. , 1998, British Journal of Cancer.

[2]  K. Burgess,et al.  3,5-Diaryl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) Dyes: Synthesis, Spectroscopic, Electrochemical, and Structural Properties , 1999 .

[3]  C. Hopper,et al.  Photodynamic therapy: a clinical reality in the treatment of cancer. , 2000, The Lancet. Oncology.

[4]  I. Kochevar,et al.  Photosensitized production of singlet oxygen. , 2000, Methods in enzymology.

[5]  N. Oku,et al.  Photodynamic therapy targeted to tumor-induced angiogenic vessels. , 2001, Cancer letters.

[6]  H. Bergh,et al.  A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. , 2001, Investigative ophthalmology & visual science.

[7]  A. Oseroff,et al.  Mitochondria-based photodynamic anti-cancer therapy. , 2001, Advanced drug delivery reviews.

[8]  Patrizia Agostinis,et al.  Phosphorylation of Bcl-2 in G2/M Phase-arrested Cells following Photodynamic Therapy with Hypericin Involves a CDK1-mediated Signal and Delays the Onset of Apoptosis* , 2002, The Journal of Biological Chemistry.

[9]  Sol Kimel,et al.  Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for photosensitizers administered intraperitoneally (IP) into the chick embryo , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[10]  R. Jain,et al.  Photodynamic therapy for cancer , 2003, Nature Reviews Cancer.

[11]  William M Gallagher,et al.  In vitro demonstration of the heavy-atom effect for photodynamic therapy. , 2004, Journal of the American Chemical Society.

[12]  P. Hynninen,et al.  Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. , 2004, Journal of photochemistry and photobiology. B, Biology.

[13]  C. Sibata,et al.  Photosensitizers in clinical PDT. , 2004, Photodiagnosis and photodynamic therapy.

[14]  N. Oku,et al.  Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. , 2004, Cancer letters.

[15]  R. Steiner,et al.  PDT with TOOKAD(®) studied in the chorioallantoic membrane of fertilized eggs. , 2005, Photodiagnosis and photodynamic therapy.

[16]  S. Teo,et al.  p53 Status does not affect photodynamic cell killing induced by hypericin , 2006, Cancer Chemotherapy and Pharmacology.

[17]  Y. Urano,et al.  Highly efficient and photostable photosensitizer based on BODIPY chromophore. , 2005, Journal of the American Chemical Society.

[18]  B. Pogue,et al.  Vascular and cellular targeting for photodynamic therapy. , 2006, Critical reviews in eukaryotic gene expression.

[19]  H. McBride,et al.  Mitochondria: More Than Just a Powerhouse , 2006, Current Biology.

[20]  E. Akkaya,et al.  Water soluble distyryl-boradiazaindacenes as efficient photosensitizers for photodynamic therapy. , 2006, Chemical communications.

[21]  Y. Mély,et al.  Convenient method to access new 4,4-dialkoxy- and 4,4-diaryloxy-diaza-s-indacene dyes: Synthesis and spectroscopic evaluation. , 2007, The Journal of organic chemistry.

[22]  Robert Gurny,et al.  The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. , 2007, Advanced drug delivery reviews.

[23]  K. Burgess,et al.  Spectral dispersion and water solubilization of BODIPY dyes via palladium-catalyzed C-H functionalization. , 2007, Organic letters.

[24]  K. Burgess,et al.  Syntheses and spectral properties of functionalized, water-soluble BODIPY derivatives. , 2008, The Journal of organic chemistry.

[25]  K. Burgess,et al.  A new synthesis of symmetric boraindacene (BODIPY) dyes. , 2008, Chemical communications.

[26]  R Lecomte,et al.  Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment , 2009, British Journal of Cancer.